Comparative Pharmacology
Head-to-head clinical analysis: ROCKLATAN versus TYRVAYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROCKLATAN versus TYRVAYA.
ROCKLATAN vs TYRVAYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Latanoprost is a prostaglandin F2α analogue that reduces intraocular pressure by increasing uveoscleral outflow of aqueous humor. It acts as a selective FP receptor agonist.
Netarsudil is a Rho kinase (ROCK) inhibitor. It increases trabecular outflow by inhibiting ROCK, which reduces cytoskeletal tension and cell adhesion in the trabecular meshwork, thereby improving aqueous humor drainage and lowering intraocular pressure.
One drop in the affected eye(s) once daily in the evening.
One drop of 0.03% ophthalmic solution in each affected eye once daily in the evening
None Documented
None Documented
Terminal elimination half-life: 17 hours (range 12–24 h); supports once-daily dosing.
Terminal elimination half-life is approximately 3.5 hours, supporting twice-daily dosing.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites.
Primarily renal excretion (approximately 60% as unchanged drug and metabolites), with biliary/fecal elimination accounting for about 30%.
Category C
Category C
Ophthalmic Glaucoma Agent
Ophthalmic Glaucoma Agent